Trial Profile
Multicenter Pilot Study of BB3 to Improve Renal Function in Patients With Signs and Symptoms of Significant Renal Injury After Kidney Transplantation and at Risk for Dialysis
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Jun 2023
Price :
$35
*
At a glance
- Drugs Terevalefim (Primary)
- Indications Renal failure
- Focus Therapeutic Use
- Sponsors Angion Biomedica; Elicio Therapeutics
- 01 Jun 2023 According to an Elicio Therapeutics media release, Angion Biomedica merged with the Elicio Therapeutics and the combined company is called as Elicio Therapeutics.
- 06 Apr 2020 Results assessing the safety and efficacy of ANG-3777 in subjects who have undergone kidney transplantation and had signs of AKI placing them at high risk for dialysis
- 04 May 2015 Planned End Date changed from 1 Apr 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov record.